Related Experiment Video
Updated: Aug 14, 2026
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Hepatitis B: a case for prenatal screening of all patients
Insights
Hepatitis B screening in pregnant women found 0.54% positivity, often without identifiable risk factors. Delayed testing prevented timely interventions for mothers and newborns, highlighting the need for earlier prenatal screening.
Area of Science:
- Obstetrics and Gynecology
- Infectious Diseases
- Public Health
Background:
- Hepatitis B virus (HBV) infection poses risks during pregnancy.
- Mass screening programs aim to identify infected individuals for timely intervention.
- Prenatal care is a critical window for managing infectious diseases in pregnant populations.
Purpose of the Study:
- To evaluate the effectiveness of a mass screening program for hepatitis B surface antigen (HBsAg) in an obstetric population.
- To determine the prevalence of HBsAg seropositivity and associated risk factors.
- To assess the timeliness of interventions for mothers and neonates based on screening results.
Main Methods:
- Retrospective review of medical records for obstetric patients screened for HBsAg.
- Analysis of screening dates, HBsAg results, identified risk factors, and timing of neonatal treatment.
- Calculation of HBsAg prevalence and assessment of intervention delays.
Main Results:
- HBsAg seropositivity prevalence was 0.54% in the obstetric population.
- 67% of positive cases lacked identifiable risk factors via routine prenatal history.
- Neonatal treatment occurred later than 12 hours post-delivery in 82% of cases due to delayed results.
Conclusions:
- Routine prenatal screening for HBsAg is crucial, especially in low socioeconomic status populations.
- Screening by 34 weeks' gestation is recommended to ensure timely isolation and neonatal immunoprophylaxis.
- Current screening protocols may not provide results early enough for effective intrapartum and neonatal management.
Abstract:
Evaluation of a mass screening program to detect hepatitis B surface antigen in the obstetric population of Shands Hospital, University of Florida in Gainesville, from January 1, 1983, through December 31, 1985, was undertaken. Prevalence of hepatitis B surface antigen seropositivity was 0.54%. Review of medical records revealed that 67% of patients with positive hepatitis B surface antigen screens had no risk factors identifiable by routine prenatal history. Although all patients were screened on admission to the hospital, the results of the immunoassay were not available in time for staff to institute isolation procedures for the laboring mother or unwashed neonate. In 82% of the cases, treatment of neonates occurred later than 12 hours after delivery (the current Centers for Disease Control recommendation). It is recommended that prenatal screening of all patients with a hepatitis B surface antigen immunoassay be done by 34 weeks' gestation where the patient population is of predominantly low socioeconomic status to ensure appropriate isolation and timely neonatal immunoprophylaxis.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
04:11Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
Related Concept Videos
01:35Pedigree Analysis
01:28Development of the Oral Microbiota
01:25Hepatitis
01:28Viral Hepatitis I: Introduction